Millburn, NJ, United States of America

Ihor E Kopka

This inventor holds 21 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp.. Active years: 1987-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ihor E Kopka. Retrieved from https://idiyas.com/inventor/ihor-e-kopka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 21 

% Patents Active = 90.5


 

Average Co-Inventor Count = 5.4

ph-index = 10

Forward Citations = 222(Granted Patents)


Location History:

  • Newark, NJ (US) (1987 - 1990)
  • Millburn, NJ (US) (1994 - 2000)
  • Hampton, NJ (US) (2012 - 2014)
  • Warren, NJ (US) (2003 - 2015)

Company Filing History:


Years Active: 1987-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Receptor Antagonists
Beta 3 Adrenergic Agonists
Cell Adhesion Inhibitors
Peptidyl Derivatives
Antidegenerative Agents
Thiazoles
Pyrimidines
Spiroethercycloalkyl Compounds
Diphenyl Substituted Alkanes
Hydroxymethyl Pyrrolidines
Tachykinin Receptor Antagonists
4-Aza-5.alpha.-Androstan-ones
21 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Ihor E Kopka

Introduction:

Ihor E Kopka, a prolific inventor based in Millburn, NJ (US), has left an indelible mark in the field of pharmaceuticals with his groundbreaking patents. With a total of 21 patents to his name, Kopka's contributions have significantly advanced the realms of cardiovascular and immune disorder treatments.

Latest Patents:

Kopka's latest patents include Platelet-activating factor receptor antagonists, encompassing cyclohexyl sulfonamide compounds that serve as potent PAF receptor antagonists. These compounds exhibit promising potential in treating atherosclerosis and various PAF-mediated disorders such as inflammatory, cardiovascular, and immune disorders. Additionally, his invention of Diphenyl substituted alkanes as flap inhibitors has unveiled compounds that act as 5-lipoxygenase activating protein inhibitors. These compounds offer therapeutic benefits in combating atherosclerosis, asthma, allergies, inflammation, and providing cytoprotective effects.

Career Highlights:

Throughout his career, Ihor E Kopka has collaborated with esteemed pharmaceutical companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His innovative mindset and dedication to advancing pharmaceutical research have propelled him to the forefront of the industry, where his patents continue to make a significant impact on healthcare and treatment advancements.

Collaborations:

Kopka has had the privilege of collaborating with notable coworkers, including Philippe L Durette and William K Hagmann. Together, they have contributed to pioneering research and development projects that have reshaped the landscape of pharmaceutical innovations.

Conclusion:

In conclusion, Ihor E Kopka's inventive spirit and unwavering commitment to progress have solidified his position as a trailblazer in the pharmaceutical industry. His patents stand as a testament to his profound contributions towards addressing critical medical needs and improving the quality of life for individuals worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…